CONCENTRAID
LOE ApproachingNDANASALSOLUTION
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CONCENTRAID is a nasal solution small-molecule NDA approved in 1990 by Ferring Pharmaceuticals. The specific indication and mechanism of action are not publicly documented in available data. This product represents a legacy therapeutic option in the nasal delivery space.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity; expect transition-focused teams and potential workforce restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CONCENTRAID has zero linked job openings, reflecting its mature lifecycle stage and limited active expansion. Working on this product typically involves transition planning, market defense, and portfolio lifecycle optimization rather than growth-focused innovation.
Brand ManagerProduct Manager
Worked on CONCENTRAID at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.